Stomach and gastroesophageal cancers have demonstrated advantages in treatment when combined with chemotherapy and the use of immune checkpoint inhibitors (ICIs) like programmed cell death receptor-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) inhibitors8–10. The gene discussed is CD274; the disease is digestive system neoplasm.